Correction: Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

Abhishek D. Garg; Sanne Elsen; Dmitri V. Krysko; Peter Vandenabeele; Peter de Witte; Patrizia Agostinis

doi:10.18632/oncotarget.25721

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

PDF | How to cite

Oncotarget. 2018; 9:29284-29284. https://doi.org/10.18632/oncotarget.25721

Metrics: PDF 1477 views | ?

Abhishek D. Garg¹, Sanne Elsen², Dmitri V. Krysko^3,4, Peter Vandenabeele^3,4, Peter de Witte² and Patrizia Agostinis¹

¹Cell Death Research & Therapy (CDRT) Unit, Department of Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium
²Laboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
³Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
⁴Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

Published: June 26, 2018

This article has been corrected: The correct Supplementary Figure S2C is given below. The authors' explanation is as follows:

Due to erroneous figure processing and oversight, unintended mistakes occurred during the assembly of Supplementary Figure S2C - specifically, the BiP/Grp78, CHOP and Actin panels for the AY27-PDT samples only. Using the source/raw data, we have now generated the correct Supplementary Figure S2C.

The authors apologize for the oversight. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript.

Original article: Oncotarget. 2015; 6:26841-26860. DOI: https://doi.org/10.18632/oncotarget.4754.

Supplementary Figure S2: Rat bladder carcinoma AY27 cells were treated or not (i.e. untreated controls/CNTR) with Hypericin-based Photodynamic Therapy (Hyp-PDT; 150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or mitoxantrone (MTX; 1 μM). C. immunoblotting for other ER stress markers like upregulation of BiP/GRP78 or CHOP levels at indicated recovery time-points. The calculations based on band densitometry analysis are mentioned as applicable.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25721

Publication Alerts

Corrections:

Correction: Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal